These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

133 related items for PubMed ID: 10606174

  • 1. Prognostic relevance of TP53 mutations, p53 protein, Ki-67 index and conventional histological grading in oligodendrogliomas.
    Hagel C, Krog B, Laas R, Stavrou DK.
    J Exp Clin Cancer Res; 1999 Sep; 18(3):305-9. PubMed ID: 10606174
    [Abstract] [Full Text] [Related]

  • 2. The prognostic significance of p53 and bcl-2 expression in lung adenocarcinoma and its correlation with Ki-67 growth fraction.
    Ishida H, Irie K, Itoh T, Furukawa T, Tokunaga O.
    Cancer; 1997 Sep 15; 80(6):1034-45. PubMed ID: 9305703
    [Abstract] [Full Text] [Related]

  • 3. Prognostic significance of p53, bcl-2 and Ki-67 in high risk superficial bladder cancer.
    Stavropoulos NE, Filiadis I, Ioachim E, Hastazeris K, Tsimaris I, Kalogeras D, Stefanaki S, Agnantis NJ.
    Anticancer Res; 2002 Sep 15; 22(6B):3759-64. PubMed ID: 12552989
    [Abstract] [Full Text] [Related]

  • 4. Prognostic factors in prostate cancer.
    Stattin P.
    Scand J Urol Nephrol Suppl; 1997 Sep 15; 185():1-46. PubMed ID: 9249905
    [Abstract] [Full Text] [Related]

  • 5. Bilharzial related, organ confined, muscle invasive bladder cancer: prognostic value of apoptosis markers, proliferation markers, p53, E-cadherin, epidermal growth factor receptor and c-erbB-2.
    Haitel A, Posch B, El-Baz M, Mokhtar AA, Susani M, Ghoneim MA, Marberger M.
    J Urol; 2001 May 15; 165(5):1481-7. PubMed ID: 11342901
    [Abstract] [Full Text] [Related]

  • 6. Prognostic value of the proliferation-related antigen Ki-67 in oligodendrogliomas.
    Kros JM, Hop WC, Godschalk JJ, Krishnadath KK.
    Cancer; 1996 Sep 01; 78(5):1107-13. PubMed ID: 8780550
    [Abstract] [Full Text] [Related]

  • 7. Assessment of biological prognostic factors provides clinically relevant information in patients with diffuse large B-cell lymphoma--a Nordic Lymphoma Group study.
    Jerkeman M, Anderson H, Dictor M, Kvaløy S, Akerman M, Cavallin-Ståhl E, Nordic Lymphoma Group study.
    Ann Hematol; 2004 Jul 01; 83(7):414-9. PubMed ID: 15085385
    [Abstract] [Full Text] [Related]

  • 8. Prognostic significance of bcl-2 expression in stage III breast cancer patients who had received doxorubicin and cyclophosphamide followed by paclitaxel as adjuvant chemotherapy.
    Lee KH, Im SA, Oh DY, Lee SH, Chie EK, Han W, Kim DW, Kim TY, Park IA, Noh DY, Heo DS, Ha SW, Bang YJ.
    BMC Cancer; 2007 Apr 12; 7():63. PubMed ID: 17430582
    [Abstract] [Full Text] [Related]

  • 9. Survival analysis of presumptive prognostic markers among oligodendrogliomas.
    McLendon RE, Herndon JE, West B, Reardon D, Wiltshire R, Rasheed BK, Quinn J, Friedman HS, Friedman AH, Bigner DD.
    Cancer; 2005 Oct 15; 104(8):1693-9. PubMed ID: 16116609
    [Abstract] [Full Text] [Related]

  • 10. Proliferative activity (MIB-1 index) is an independent prognostic parameter in patients with high-grade soft tissue sarcomas of subtypes other than malignant fibrous histiocytomas: a retrospective immunohistological study including 216 soft tissue sarcomas.
    Jensen V, Sørensen FB, Bentzen SM, Ladekarl M, Nielsen OS, Keller J, Jensen OM.
    Histopathology; 1998 Jun 15; 32(6):536-46. PubMed ID: 9675593
    [Abstract] [Full Text] [Related]

  • 11. Role of gemistocytes in astrocytoma progression.
    Watanabe K, Tachibana O, Yonekawa Y, Kleihues P, Ohgaki H.
    Lab Invest; 1997 Feb 15; 76(2):277-84. PubMed ID: 9042164
    [Abstract] [Full Text] [Related]

  • 12. Immunohistochemical detection of EGFR, p185(erbB-2), Bcl-2 and p53 in breast carcinomas in pre-menopausal and post-menopausal women.
    Talley L, Chhieng DC, Bell WC, Grizzle WE, Frost AR.
    Biotech Histochem; 2008 Feb 15; 83(1):5-14. PubMed ID: 18568671
    [Abstract] [Full Text] [Related]

  • 13. Influence of TP53 gene alterations and c-erbB-2 expression on the response to treatment with doxorubicin in locally advanced breast cancer.
    Geisler S, Lønning PE, Aas T, Johnsen H, Fluge O, Haugen DF, Lillehaug JR, Akslen LA, Børresen-Dale AL.
    Cancer Res; 2001 Mar 15; 61(6):2505-12. PubMed ID: 11289122
    [Abstract] [Full Text] [Related]

  • 14. Prognostic values of stromal proportion and PCNA, Ki-67, and p53 proteins in patients with resected adenocarcinoma of the lung.
    Demarchi LM, Reis MM, Palomino SA, Farhat C, Takagaki TY, Beyruti R, Saldiva PH, Capelozzi VL.
    Mod Pathol; 2000 May 15; 13(5):511-20. PubMed ID: 10824922
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Implications of prognostic markers in brain tumors.
    Grzybicki DM, Moore SA.
    Clin Lab Med; 1999 Dec 15; 19(4):833-47. PubMed ID: 10572718
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. p53 protein alterations in adult astrocytic tumors and oligodendrogliomas.
    Nayak A, Ralte AM, Sharma MC, Singh VP, Mahapatra AK, Mehta VS, Sarkar C.
    Neurol India; 2004 Jun 15; 52(2):228-32. PubMed ID: 15269478
    [Abstract] [Full Text] [Related]

  • 20. Ki-67, cyclin D1, p53 and bcl-2 expression in advanced head and neck cancer.
    Nagy B, Tiszlavicz L, Eller J, Molnar J, Thurzo L.
    In Vivo; 2003 Jun 15; 17(1):93-6. PubMed ID: 12655798
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.